These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 33002296)

  • 1. Targeted Protein Degradation as a Promising Tool for Epigenetic Upregulation of Fetal Hemoglobin.
    J Verheul TC; Trinh VT; Vázquez O; Philipsen S
    ChemMedChem; 2020 Dec; 15(24):2436-2443. PubMed ID: 33002296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fetal hemoglobin chemical inducers for treatment of hemoglobinopathies.
    Testa U
    Ann Hematol; 2009 Jun; 88(6):505-28. PubMed ID: 19011856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cell stress signaling model of fetal hemoglobin induction: what doesn't kill red blood cells may make them stronger.
    Mabaera R; West RJ; Conine SJ; Macari ER; Boyd CD; Engman CA; Lowrey CH
    Exp Hematol; 2008 Sep; 36(9):1057-72. PubMed ID: 18718415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The state of the art of fetal hemoglobin-inducing agents.
    Pavan AR; Lopes JR; Dos Santos JL
    Expert Opin Drug Discov; 2022 Nov; 17(11):1279-1293. PubMed ID: 36302760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting fetal hemoglobin expression to treat β hemoglobinopathies.
    Steinberg MH
    Expert Opin Ther Targets; 2022 Apr; 26(4):347-359. PubMed ID: 35418266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phthalides serve as potent modulators to boost fetal hemoglobin induction therapy for β-hemoglobinopathies.
    Chen WR; Chou CC; Wang CC
    Blood Adv; 2019 May; 3(9):1493-1498. PubMed ID: 31072835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic inactivation of ERF reactivates γ-globin expression in β-thalassemia.
    Bao X; Zhang X; Wang L; Wang Z; Huang J; Zhang Q; Ye Y; Liu Y; Chen D; Zuo Y; Liu Q; Xu P; Huang B; Fang J; Lao J; Feng X; Li Y; Kurita R; Nakamura Y; Yu W; Ju C; Huang C; Mohandas N; Li D; Zhao C; Xu X
    Am J Hum Genet; 2021 Apr; 108(4):709-721. PubMed ID: 33735615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of G9a methyltransferase stimulates fetal hemoglobin production by facilitating LCR/γ-globin looping.
    Krivega I; Byrnes C; de Vasconcellos JF; Lee YT; Kaushal M; Dean A; Miller JL
    Blood; 2015 Jul; 126(5):665-72. PubMed ID: 25979948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacologic induction of fetal hemoglobin production.
    Atweh G; Fathallah H
    Hematol Oncol Clin North Am; 2010 Dec; 24(6):1131-44. PubMed ID: 21075284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCL11A-targeted γ-globin gene induction by triterpenoid glycosides of Fagonia indica: A preclinical scientific validation of indigenous herb for the treatment of β-hemoglobinopathies.
    Iftikhar F; Khan MBN; Tehreem S; Kanwal N; Musharraf SG
    Bioorg Chem; 2023 Nov; 140():106768. PubMed ID: 37586133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteolysis targeting chimeras (PROTACs) for epigenetics research.
    Vogelmann A; Robaa D; Sippl W; Jung M
    Curr Opin Chem Biol; 2020 Aug; 57():8-16. PubMed ID: 32146413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fetal Hemoglobin Induction by Epigenetic Drugs.
    Lavelle D; Engel JD; Saunthararajah Y
    Semin Hematol; 2018 Apr; 55(2):60-67. PubMed ID: 29958562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Genetic Variant Ameliorates β-Thalassemia Severity by Epigenetic-Mediated Elevation of Human Fetal Hemoglobin Expression.
    Chen D; Zuo Y; Zhang X; Ye Y; Bao X; Huang H; Tepakhan W; Wang L; Ju J; Chen G; Zheng M; Liu D; Huang S; Zong L; Li C; Chen Y; Zheng C; Shi L; Zhao Q; Wu Q; Fucharoen S; Zhao C; Xu X
    Am J Hum Genet; 2017 Jul; 101(1):130-138. PubMed ID: 28669403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic variants in members of the Krüppel-like factor gene family are associated with disease severity and hydroxyurea treatment efficacy in β-hemoglobinopathies patients.
    Stratopoulos A; Kolliopoulou A; Karamperis K; John A; Kydonopoulou K; Esftathiou G; Sgourou A; Kourakli A; Vlachaki E; Chalkia P; Theodoridou S; Papadakis MN; Gerou S; Symeonidis A; Katsila T; Ali BR; Papachatzopoulou A; Patrinos GP
    Pharmacogenomics; 2019 Jul; 20(11):791-801. PubMed ID: 31393228
    [No Abstract]   [Full Text] [Related]  

  • 15. Oral administration of the LSD1 inhibitor ORY-3001 increases fetal hemoglobin in sickle cell mice and baboons.
    Rivers A; Vaitkus K; Jagadeeswaran R; Ruiz MA; Ibanez V; Ciceri F; Cavalcanti F; Molokie RE; Saunthararajah Y; Engel JD; DeSimone J; Lavelle D
    Exp Hematol; 2018 Nov; 67():60-64.e2. PubMed ID: 30125603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Epigenetic Regulators with Covalent Small-Molecule Inhibitors.
    Zhang Y; Rong D; Li B; Wang Y
    J Med Chem; 2021 Jun; 64(12):7900-7925. PubMed ID: 33599482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modifier genes in Mendelian disorders: the example of hemoglobin disorders.
    Sankaran VG; Lettre G; Orkin SH; Hirschhorn JN
    Ann N Y Acad Sci; 2010 Dec; 1214():47-56. PubMed ID: 21039591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted therapeutic strategies for fetal hemoglobin induction.
    Sankaran VG
    Hematology Am Soc Hematol Educ Program; 2011; 2011():459-65. PubMed ID: 22160074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential role of LSD1 inhibitors in the treatment of sickle cell disease: a review of preclinical animal model data.
    Rivers A; Jagadeeswaran R; Lavelle D
    Am J Physiol Regul Integr Comp Physiol; 2018 Oct; 315(4):R840-R847. PubMed ID: 30067082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA hypomethylation therapy for hemoglobin disorders: molecular mechanisms and clinical applications.
    Fathallah H; Atweh GF
    Blood Rev; 2006 Jul; 20(4):227-34. PubMed ID: 16513230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.